Ectoparasiticides Market Size, Share & Industry Analysis, By Product (Pour-on, Spot-on, Sprays, Dips, Oral tablets, Others), By Animal (Livestock, Companion), By End User (Veterinary Clinics, R & D Facilities, Farms, Others) and Regional Forecast, 2024-2032

Ectoparasiticides refer to the antiparasitic drugs which are administered in the treatment of animals diagnosed with ectoparasitic infestations or infections. Also referred to as external parasiticides, these products are used to control or eliminate the parasites that attack both the livestock and the companion animals. These drugs often work in contrast to endoparasiticides, who works against the parasites inside the animal’s body. Ectoparasiticides can be classified according to the type of parasite they work against and can be called acaricides, insecticides, tickicides, lousicides, and scabicides. Ectoparasiticides are a crucial component for the health and welfare of the animal because they cause several diseases that can be infectious or zoonotic in terms of nature. Ectoparasiticides are one of the most effective and critical tools for preventing animal diseases and for promoting animal health and welfare, safe food production, and public health. Ectoparasiticides also play a crucial role in animal health protection by preventing and controlling serious epizootic diseases. Prevention of animal diseases is also critical because they are a negative constraint to sustained agricultural development and food security and can disrupt the economic benefits of international trade in livestock commodities. The factors above are thus likely to drive the ectoparasiticides market growth during the forecast period.

The global ectoparasiticides market is anticipated to grow owing to several factors such as the increasing prevalence of animal & zoonotic diseases, and growing rate of parasitic infections to animals. Additionally, raising awareness of animal health and welfare and development of parasiticides for animal parasitic infections is likely to promote the growth of ectoparasiticides market. These trends, combined with the other factors, are expected to drive the market growth positively.

However, the factors limiting the growth of the global ectoparasiticides market are the stringent regulatory approval process, resistance to antibiotics, and the increasing cost of animal healthcare.

Key Players Covered:

The major companies covered in the global ectoparasiticides market report include Bayer AG, Elanco, Boehringer Ingelheim International GmbH, Zoetis, Ceva, Virbac, Vetoquinol S.A., Sanofi, and others.

As per the current ectoparasiticides market trends, the pour-on and spot-on segment accounted for a higher share owing to its specific formulations and effectiveness in treatment of ectoparasitic infections.

Key Insights:

• Overview of opportunity assessment in untapped market


• New product launch


• Regulatory scenario


• Key Mergers & acquisitions

Regional Analysis:

Geographically, the global ectoparasiticides market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is expected to lead the ectoparasiticides market owing to ongoing research and development for ectoparasiticides and higher animal adoption rates for animal husbandry and farming. North America accounts for the second position in the global ectoparasiticides market owing to rising pet adoption rates, increasing prevalence of animal diseases especially zoonotic and infectious, growing animal healthcare expenditure, increased demand for meat and animal-based products, and large pool of veterinarians.

Asia Pacific is the fastest emerging market due to large livestock animal pool, increasing incidences of animal disorders, increasing awareness of animal welfare and introduction of government. Latin America is likely to progress during the forecast period owing to growing awareness regarding animal health while the Middle East & Africa is expected to show restricted growth owing to lack of awareness in the region.

Segmentation

 Ectoparasiticides Industry Developments

• In November 2018, Zoetis received U.S. FDA approval for its REVOLUTION PLUS, a next-generation parasiticide for prevention of parasitic infections in cats and kittens.


• In January 2018, Elanco received U.S.FDA approval for CREDELIO, an oral treatment against fleas and ticks that are responsible to cause parasitic infections to dogs and cats.